

NewLink Genetics Announces Participation at The H.C. Wainwright Annual Global Life Sciences Conference

April 3, 2018

AMES, Iowa, April 03, 2018 (GLOBE NEWSWIRE) -- [NewLink Genetics Corporation](#) (NASDAQ:NLNK) announced today it will present at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

NewLink Genetics management will participate in a fireside chat Tuesday, April 10, 2018, entitled "Advances of Immuno-oncology" 8:00 AM – 9:00 AM CET. In addition, management will provide an overview of the Company's business during a live presentation April 10th, 1:20 PM – 1:45PM CET, and will be available for one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company's presentation, please click on the following link (www.hcwevents.com) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

A live webcast of the conference presentation will be available on the Company's website at www.newlinkgenetics.com in the "Investors & Media" section under "Events & Presentations."

About NewLink Genetics Corporation

NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.

Investor Contact:

Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
lmiller@linkp.com

Media Contact:

Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
scorreia@lavoiehealthscience.com

 [Primary Logo](#)

Source: NewLink Genetics Corporation